Proportional Hazards Violations in Phase 3 Cancer Clinical Trials: A Potential Source of Trial Misinterpretation.
Timothy A LinZachary Ryan McCawAlex KoongChristine LinJoseph Abi JaoudeRoshal R PatelRamez KouzyMolly B El AlamAlexander D SherrySonal S NoticewalaClifton David FullerCharles R ThomasRyan SunJiun-Kae Jack LeeRuitao LinYing YuanYu ShyrTomer MeirsonEthan Bernard LudmirPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
PHVs are common across therapy types, and attempts to account for PHVs in statistical design are lacking despite the potential for results exhibiting non-proportional hazards to be misinterpreted.